MediciNova, Inc. (MNOV): Price and Financial Metrics
MNOV Price/Volume Stats
| Current price | $1.68 | 52-week high | $2.71 |
| Prev. close | $1.74 | 52-week low | $1.68 |
| Day low | $1.68 | Volume | 47,800 |
| Day high | $1.73 | Avg. volume | 42,981 |
| 50-day MA | $1.91 | Dividend yield | N/A |
| 200-day MA | $2.17 | Market Cap | 82.40M |
MNOV Stock Price Chart Interactive Chart >
MediciNova, Inc. (MNOV) Company Bio
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. The company was founded in 2000 and is based in La Jolla, California.
Latest MNOV News From Around the Web
Below are the latest news stories about MEDICINOVA INC that investors may wish to consider to help them evaluate MNOV as an investment opportunity.
MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update New Data for MN-166 in GBM Presented at SNO On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) were presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) ( Lauko et al., 2023 ). The Phase |
The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitableLong term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning! |
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-OncologyLA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner Co |
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaLA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on a |
MNOV Price Returns
| 1-mo | -9.19% |
| 3-mo | -25.33% |
| 6-mo | -21.86% |
| 1-year | -30.29% |
| 3-year | -72.41% |
| 5-year | -81.31% |
| YTD | -18.05% |
| 2022 | -23.51% |
| 2021 | -49.05% |
| 2020 | -21.96% |
| 2019 | -17.50% |
| 2018 | 26.28% |
Loading social stream, please wait...